Page last updated: 2024-12-05

bulbocapnine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

bulbocapnine: was heading 1975-94 (Prov 1975-90); use APORPHINES to search BULBOCAPNINE 1975-94 (as Prov 1975-94); alkaloid from Corydalis cava and other plants; induces catalepsy probably due to its antagonism of DOPAMINE [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

bulbocapnine : An aporphine alkaloid that has been isolated from Corydalis and exhibits inhibitory activity against enzymes such as tyrosine 3-monooxygenase and diamine oxidase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
CorydalisgenusA plant genus of the family FUMARIACEAE (classified by some in PAPAVERACEAE) that contains isoquinoline alkaloids.[MeSH]PapaveraceaeThe poppy plant family of the order Papaverales, subclass Magnoliidae, class Magnoliopsida. These have bisexual, regular, cup-shaped flowers with one superior pistil and many stamens; 2 or 3 conspicuous, separate sepals and a number of separate petals. The fruit is a capsule. Leaves are usually deeply cut or divided into leaflets.[MeSH]
Corydalis cavaspecies[no description available]PapaveraceaeThe poppy plant family of the order Papaverales, subclass Magnoliidae, class Magnoliopsida. These have bisexual, regular, cup-shaped flowers with one superior pistil and many stamens; 2 or 3 conspicuous, separate sepals and a number of separate petals. The fruit is a capsule. Leaves are usually deeply cut or divided into leaflets.[MeSH]

Cross-References

ID SourceID
PubMed CID12441
CHEMBL ID157912
CHEBI ID3211
SCHEMBL ID678694
MeSH IDM0222863

Synonyms (29)

Synonym
6a-alpha-aporphin-11-ol, 10-methoxy-1,2-(methylenedioxy)-
5h-benzo(g)-1,3-benzodioxolo(6,5,4-de)quinolin-12-ol, 6,7,7a,8-tetrahydro-11-methoxy-7-methyl-, (s)-
bulbokaprin
einecs 206-061-1
(s)-(+)-bulbocapnine
4-hydroxy-3-methoxy-5,6-methylenedioxy-aporphin
PDSP2_000621
C09367
298-45-3
bulbocapnine
AKOS000276822
(+)-bulbocapnine
chebi:3211 ,
CHEMBL157912 ,
bdbm50016018
(s)-11-methoxy-7-methyl-6,7,7a,8-tetrahydro-5h-benzo[g][1,3]dioxolo[4'',5'':4,5]benzo[1,2,3-de]quinolin-12-ol
11-methoxy-7-methyl-6,7,7a,8-tetrahydro-5h-benzo[g][1,3]dioxolo[4'',5'':4,5]benzo[1,2,3-de]quinolin-12-ol (bulbocapnine)
unii-o0tgi865qo
o0tgi865qo ,
SCHEMBL678694
bulbocapnine [mi]
(7as)-11-methoxy-7-methyl-6,7,7a,8-tetrahydro-5h-[1,3]benzodioxolo[6,5,4-de]benzo[g]quinolin-12-ol
DTXSID20183940
buibocapnine hydrochloride
bulbocapnin
Q1003526
(12s)-17-methoxy-11-methyl-3,5-dioxa-11-azapentacyclo[10.7.1.02,6.08,20.014,19]icosa-1(20),2(6),7,14(19),15,17-hexaen-18-ol
nsc-785188
nsc785188
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
EC 1.4.3.22 (diamine oxidase) inhibitorAn EC 1.4.3.* (oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor) inhibitor that interferes with the action of diamine oxidase (EC 1.4.3.22).
EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitorAn EC 1.14.16.* (oxidoreductase acting on paired donors, reduced pteridine as one donor, incorporating 1 atom of oxygen) inhibitor that interferes with the action of tyrosine 3-monooxygenase (EC 1.14.16.2).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
oxacycleAny organic heterocyclic compound containing at least one ring oxygen atom.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
aporphine alkaloidAny benzylisoquinoline alkaloid that has a structure based on 4H-dibenzo[de,g]quinoline or its 3-methyl derivative.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DRattus norvegicus (Norway rat)IC50 (µMol)0.73950.00030.50267.7625AID313111; AID61181
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)14.02350.00010.54948.4000AID313112; AID64424
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID182828In vitro inhibition of adenylate cyclase stimulation caused by 10 uM dopamine in rat retinal tissue by 10 uM.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Aporphines as antagonists of dopamine D-1 receptors.
AID403982Antiplatelet activity against arachidonic acid-induced rabbit platelet aggregation assessed as platelet aggregation at 100 ug/ml preincubated for 3 mins by turbidimetric method relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Bioactive alkaloids from Illigera luzonensis.
AID313101Reduction of dopamine level in catecholamine-inducing rat PC12 cells2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Advances in development of dopaminergic aporphinoids.
AID403981Antiplatelet activity against ADP-induced rabbit platelet aggregation assessed as platelet aggregation at 100 ug/ml preincubated for 3 mins by turbidimetric method relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Bioactive alkaloids from Illigera luzonensis.
AID182827In vitro inhibition of adenylate cyclase stimulation caused by 10 uM dopamine in rat retinal tissue by 0.1 uM.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Aporphines as antagonists of dopamine D-1 receptors.
AID64424In vitro binding affinity towards rat Dopamine receptor D2 by [3H]spiperone displacement.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Aporphines as antagonists of dopamine D-1 receptors.
AID403983Antiplatelet activity against collagen-induced rabbit platelet aggregation assessed as platelet aggregation at 100 ug/ml preincubated for 3 mins by turbidimetric method relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Bioactive alkaloids from Illigera luzonensis.
AID398830Antiplatelet activity against PAF-induced rabbit platelet aggregation assessed as platelet aggregation at 100 ug/ml preincubated for 3 mins by turbidimetric method relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Bioactive alkaloids from Illigera luzonensis.
AID313111Displacement of [3H]SCH-23390 from rat dopamine D1 receptor2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Advances in development of dopaminergic aporphinoids.
AID61181In vitro binding affinity towards rat Dopamine receptor D1 by [3H]SCH-23390 displacement.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Aporphines as antagonists of dopamine D-1 receptors.
AID313112Displacement of [3H]raclopride from rat dopamine D2 receptor2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Advances in development of dopaminergic aporphinoids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199038 (74.51)18.7374
1990's7 (13.73)18.2507
2000's2 (3.92)29.6817
2010's4 (7.84)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other60 (96.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]